Biography
Dr. Maurizio Fava has been Director of the Depression Clinical and Research Program at Massachusetts General Hospital since 1990. Dr. Fava obtained his medical degree and completed residency training in endocrinology at the University of Padua School of Medicine. He then moved to the United States and completed residency training in psychiatry at MGH.
Under Dr. Fava's direction, the Depression Clinical and Research Program has become one of the most highly regarded depression programs in the country, a true model for academic programs that link, in a bi-directional fashion, clinical and research work. The number of ongoing projects has grown from five in 1990 to the more than 40 currently.
The clinician-scientists of the Depression Clinical and Research Program conduct research projects in a variety of areas, including neuroimaging, genetics, neurophysiology, neuroendocrinology, pharmacotherapy, neurotherapeutics, and psychotherapy. Dr. Fava has also been successful in obtaining funding for the program, as principal or co-principal investigator, from both the National Institutes of Health and industry for a total of more than $20,000,000 in the past ten years. Dr. Fava's prominence in the field is reflected by his role as the co-principal investigator of STAR*D, the largest study ever conducted in the area of depression.
Dr. Fava has authored or co-authored more than 300 original articles published in medical journals with international circulation. He has also edited four books, and published more than 50 chapters and 400 abstracts. He has received several awards during his career and is on the editorial board of four international medical journals. His major research interests have been the development of effective short-term and long-term strategies in the treatment of depression and depressive subtypes, and the study of treatment-resistant depression. Since 1990, Dr. Fava has also mentored more than 20 trainees who have gone on to become lead investigators in the area of depression.
Dr. Fava is also a well-known national and international speaker, having given more than 200 presentations at national and international meetings during his career in psychiatry. He is currently Vice Chair for the Department of Psychiatry and Director of the Depression Clinical and Research Program at the Massachusetts General Hospital and Professor of Psychiatry at Harvard Medical School.
Disclosure
Research Support
Abbott Laboratories, Alkermes, Aspect Medical Systems, Astra-Zeneca, Bio Research, BrainCells Inc., Bristol-Myers Squibb, Cephalon, Clinical Trial Solutions, Eli Lilly & Co., Forest Pharmaceuticals Inc., Ganeden, GlaxoSmithKline, J&J Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, NARSAD, NCCAM, NIDA, NIMH, Novartis, Organon Inc., PamLab LLC, Pfizer Inc, Pharmavite, Roche, Sanofi-Aventis, Shire, Solvay Pharmaceuticals Inc., Synthelabo, and Wyeth-Ayerst Laboratories
Speaking/Publishing
Advanced Meeting Partners, American Psychiatric Association, Astra-Zeneca, Belvoir, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Eli Lilly & Co., Forest Pharmaceuticals Inc., GlaxoSmithKline, Imedex , Novartis, Organon Inc., Pfizer Inc, PharmaStar, MGH Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed-Elsevier, UBC, Wyeth-Ayerst Laboratories
Advisory/Consulting
Abbott Laboratories, Amarin, Aspect Medical Systems , Astra-Zeneca, Auspex Pharmaceuticals, Bayer AG, Best Practice Project Management Inc, Biovail Pharmaceuticals Inc., BrainCells Inc, Bristol-Myers Squibb, Cephalon, Clinical Trials Solutions, CNS Response, Compellis, Cypress Pharmaceuticals, Dov Pharmaceuticals, Eli Lilly & Co., EPIX Pharmaceuticals, Fabre-Kramer, Pharmaceuticals Inc., Forest Pharmaceuticals Inc., GlaxoSmithKline, Grunenthal GmBH, Janssen Pharmaceuticals, Jazz Pharmaceuticals, J&J Pharmaceuticals, Knoll Pharmaceuticals, Labopharm , Lorex Pharmaceuticals, Lundbeck , MedAvante Inc. Merck, Methylation Sciences, Neuronetics, Novartis, Nutrition 21, Organon Inc., PamLab LLC, Pfizer Inc , PharmaStar , Pharmavite , Precision Human Biolaboratory, Roche, Sanofi-Aventis, Sepracor, Schering-Plough, Solvay Pharmaceuticals Inc., Somaxon, Somerset Pharmaceuticals, Synthelabo, Takeda, Tetragenex, Transcept Pharmaceuticals, Vanda Pharmaceuticals Inc, and Wyeth-Ayerst Laboratories
Equity Holdings
Compellis
Royalty/Patent, Other Income
Patent applications for SPCD and for a combination of azapirones and bupropion in MDD, copyright royalties for the MGH CPFQ, SFI, ATRQ, DESS, and SAFER
Last updated: 7/27/2010
Courses
Residual Symptoms of Depression: Lethargy and Cognitive Compromise
Major Depressive Disorder: Present State of Clinical Care, Assessing Treatment Challenges
New Approaches to the Treatment of Depression: Optimizing Efficacy and Patient Tolerability
Psychopharmacology Updates: A Comprehensive Review of Evidence-Based Approaches
Special Topics in Management of Major Depressive Disorder and Related Mood Disorders
Difficult to Treat Depression: Addressing Barriers to Recovery (Boston, MA)
Virtual Grand Rounds: Spring 2011 Series -- Individual Registration
Virtual Grand Rounds: Summer 2011 Series -- Individual Registration
Virtual Grand Rounds: Fall 2011 Series -- Individual Registration
Virtual Grand Rounds: Diagnosis and management of complicated grief and loss
Virtual Grand Rounds: Update on the psychotropic drug management of postpartum depression
Virtual Grand Rounds: Recent advances in the psychological treatment of PTSD
Virtual Grand Rounds: Where did clinical judgement go in clinical practice?
Virtual Grand Rounds: Neurosurgical treatments for psychiatric illness
Virtual Grand Rounds: Challenges remaining in the diagnosis of pediatric bopolar disorder
Virtual Grand Rounds: Treatment of Mood disorders during pregnancy: Lessons from Two decades
Acupuncture and Cranial Electrical Stimulation (CES) in Psychiatry
The Role of Fatigue in Depressive Disorders & Using Biomarkers for Personalized Treatment (Boston)